Trial Profile
A Multicenter, Two Part Open-Label, Phase 1B Clinical Study of CMP-001 Administered Either in Combination With Pembrolizumab or as a Monotherapy in Subjects With Advanced Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Vidutolimod (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Checkmate Pharmaceuticals
- 09 Jan 2023 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Results of post hoc analysis (n=159) assessing the safety and clinical activity in the subgroup of pts with AI on CRT presented at the 47th European Society for Medical Oncology Congress
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research